Indivior Beats Humana, Centene in Suboxone Racketeering Appeal

Humana Inc. and Centene Corp. are ineligible to seek racketeering damages from Indivior Inc. over its alleged scheme to corner the opioid cessation market, a federal appeals court ruled Thursday, citing the insurers’ status as indirect drug purchasers.

The US Court of Appeals for the Third Circuit declined to revive separate lawsuits by Humana and Centene, which accused Indivior of switching to a new “sublingual film” version of its drug Suboxone just as comparable generics were set to debut in traditional tablet form.

The suits—consolidated with several class actions and attorney general claims as part of a multidistrict litigation—involve complex ...